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A B S T R A C T
Neural stem cell (NSC) neuronal differentiation requires a metabolic shift towards oxidative phosphorylation.
We now show that a branched-chain amino acids-driven, persistent metabolic shift toward energy metabolism is
required for full neuronal maturation. We increased energy metabolism of differentiating neurons derived both
from murine NSCs and human induced pluripotent stem cells (iPSCs) by supplementing the cell culture medium
with a mixture composed of branched-chain amino acids, essential amino acids, TCA cycle precursors and co-
factors. We found that treated differentiating neuronal cells with enhanced energy metabolism increased: i) total
dendritic length; ii) the mean number of branches and iii) the number and maturation of the dendritic spines.
Furthermore, neuronal spines in treated neurons appeared more stable with stubby and mushroom phenotype
and with increased expression of molecules involved in synapse formation. Treated neurons modified their
mitochondrial dynamics increasing the mitochondrial fusion and, consistently with the increase of cellular ATP
content, they activated cellular mTORC1 dependent p70S6 K1 anabolism. Global transcriptomic analysis further
revealed that treated neurons induce Nrf2 mediated gene expression. This was correlated with a functional
increase in the Reactive Oxygen Species (ROS) scavenging mechanisms.
In conclusion, persistent branched-chain amino acids-driven metabolic shift toward energy metabolism en-
hanced neuronal differentiation and antioxidant defences. These findings offer new opportunities to pharma-
cologically modulate NSC neuronal differentiation and to develop effective strategies for treating neurodegen-
erative diseases.
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1. Introduction
Pharmacological modulation of neuronal morphogenesis and ma-
turation has been proposed as an attractive therapeutic opportunity for
the treatment of neurological diseases, including stroke, traumatic
brain injury and spinal cord injury.
In the last few years, it has become clear that every cellular phe-
notype is characterized by a defined metabolic signature [1,2]. The
brain has high energy requirements contributing to 25 % of the body
glucose utilization [3] and accounting for more than 20 % of the body
oxygen consumption. Neurons need high ATP content to support
membrane remodelling, synaptic spine formation, and generation of
transmembrane resting and action potential [4–6]. Such high metabolic
costs impose to these cells the use of the oxidative metabolism [7],
which produces higher ATP yields than glycolysis. Neurons, during the
process of differentiation from immature precursors, typically show
increased oxidative phosphorylation [7–10] and such metabolic shift
towards oxidative metabolism is required for neuronal differentiation.
The increase of cellular ATP content, a potent allosteric inhibitor of
AMPK, activates the mTOR-dependent anabolic pathway in neurons
[11]. Accordingly, the inhibition of oxidative metabolism impairs
neuronal differentiation and drives neural stem cells (NSCs) to a pro-
liferative and less differentiated state [12]. Moreover, nutrients, in-
cluding leucine, can also directly increase mTOR-dependent anabolic
pathway [13]. Brain damage is followed by an injury-induced activa-
tion of neural precursors characterized by increased cell proliferation
and migration towards the lesion site. However, the migrated pro-
genitors contributing to the parenchymal reaction mostly express
markers of immature neural differentiation and fail to become fully
differentiated neuronal cells [14,15].
Whether a branched-chain amino acid-driven persistent increase of
energy metabolism in differentiating neurons may be a new strategy to
enhance neuronal maturation is unknown. We previously demonstrated
that supplementation with a balanced formula of essential amino acids
enriched in branched-chain amino acids activated mTOR-dependent
anabolic pathway, increased oxidative phosphorylation and reduced
Reactive Oxygen Species (ROS) production in different tissues [16–22].
Studies on mouse models of traumatic brain injury (TBI) have shown
that dietary supplementation of branched-chain amino acids ameliorate
cognitive impairment [23]. Following pilot human studies, amino acid
supplementation emerged as promising treatment options for TBI
[17,24]. In order to obtain an optimal and persistent increase in energy
metabolism in differentiating neurons, we used a formulation, referred
to as α5, composed of branched-chain amino acids, tricarboxylic acid
(TCA) cycle intermediates, and co-factors optimized to improve mi-
tochondrial function in different cell lines (see Table S1) [25]. We
tested the effect of α5 treatment on the phenotype of neuronal differ-
entiating cells and we studied the molecular events associated. As
neuronal precursors, we used both NSCs from the subventricular zone
(SVZ-NSCs; sorted for the expression of Prominin) and the NSCs present
in meninges (M-NSCs; sorted for the expression of PDGFRß), that we
have previously identified and characterized [14,15,26–30]. To further
test whether the effects of α5 were restricted to murine NSCs, or they
were conserved in human neuronal differentiation, we confirmed our
results on motor neurons derived from human induced pluripotent stem
cells (iPSCs).
2. Material and methods
2.1. Neural stem cell culture
Animal housing and all experimental procedures were approved by
the Istituto Superiore di Sanità (I.S.S., National Institute of Health;
protocol n. 237/2016-PR and n.72/2018-PR, Italy) and the Animal
Ethics Committee (C.I.R.S.A.L., Centro Interdipartimentale di Servizio
alla Ricerca Sperimentale) of the University of Verona (Italy). Meninges
were extracted from WT CD1 P0 pup brains, then dissociated as pre-
viously described [28,30] and immunomagnetically sorted for PDGFRß
expression (Biotinylated goat anti-PDGFRß 1:50, BAF1042; Strepta-
vidin MicroBeads [Miltenyi], 130-048-101) according to manu-
facturer’s instructions. Subventricular zone-derived (VZ/SVZ) cells
were extracted from WT CD1 P0 pup brains, then dissociated and im-
munomagnetically sorted for Prominin expression (mouse anti-Pro-
minin microbeads, 1:5 [Miltenyi], 120-003-396]. PDGFRß+ meningeal-
derived neural stem cells (meningeal NSCs) and Prominin+ VZ/SVZ-
sorted cells (SVZ-derived NSCs) were then cultured as neurospheres as
described in Bifari et al., 2009. Briefly, cells were seeded into 6-well
plates (Falcon) in 3 mL of neurosphere culture medium (DMEM/F-12
GlutaMAX [Thermo Fisher Scientific], containing 2% B27 supplement
[Thermo Fisher Scientific], 1% N2 supplement [Thermo Fisher Scien-
tific], 1% penicillin-streptomycin (P/S) [Thermo Fisher Scientific], plus
20 ng/mL epidermal growth factor (EGF) [Peprotech Inc.] and 20 ng/
mL basic fibroblast growth factor (bFGF) [Peprotech Inc.]). Every 2–3
days, half of the medium (approximately 1.5 mL) was substituted with
fresh NS medium. After 7–10 days, neurospheres were collected, cen-
trifuged, mechanically dissociated to a single-cell suspension and fur-
ther expanded in NS medium into T75 flasks.
2.2. Human induced pluripotent stem cells (iPSCs) generation and culture
iPSCs were obtained reprogramming skin biopsy-derived fibroblasts
of two healthy donors with previously written informed consent from
the participants. The CytoTune-iPS 2.0 Sendai Reprogramming Kit was
used following manufacturer’s instructions. The karyotype analysis
confirmed that no chromosomal alterations occurred during repro-
gramming. The iPSCs were expanded for at least 6 passages and fully
characterized for the expression of the pluripotency markers Alkaline
Phospatase (ALP), TRA-1-60 and Stage-specific embryonic antigen-4
(SSEA-4) by immunocytochemistry and Sex determining region Y-box 2
(Sox2), Octamer-binding transcription factor 3 (Oct 3), Octamer-
binding transcription factor 4 (Oct 4) and Homeobox protein Nanog
(Nanog) by RT-PCR. The ability of iPSCs to spontaneously differentiate
into the three germ layer cells was also verified, further confirming
their pluripotency. Cells were differentiated into motor neurons as
previously described [31] for the subsequent analysis.
2.3. Neuronal differentiation protocol
2.3.1. Murine NSCs
We differentiated meningeal NSCs and SVZ-derived NSCs into ma-
ture neurons (M-neurons and SVZ-neurons, respectively) as previously
described [30]. Briefly, neurospheres were collected, centrifuged and
mechanically dissociated to a single-cell suspension. Then, 1 × 105
cells were plated into a poly-D-lysine (10 μg/mL) [Sigma-Aldrich]-
coated cover slip in the differentiation medium (Neuron Chow, com-
posed by Neurobasal Medium [Thermo Fisher Scientific] containing 2%
B27 supplement, 200 mM glutamine [Thermo Fisher Scientific], 10 mM
glutamate [Sigma-Aldrich] and 1% P/S plus 50 ng/mL brain-derived
nerve growth factor (BDNF) [Peprotech Inc.]). The medium was
changed every 2–3 days. After 10 days in vitro (DIV), cells were washed
in PBS 1X and then fixed for 10 minutes in PFA 4% before im-
munostaining.
2.3.2. Human induced pluripotent stem cells (iPSCs)
Cells were differentiated into motor neurons as previously described
[31] for the subsequent analysis. Cells were seeded at high density (18
× 103 cells/cm2) for RNA and protein extraction, and low density (5 ×
103 cells/cm2) for immunocytochemical analysis and Seahorse cell
culture microplates.
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2.4. In vitro cell supplementation
Neuronal cells (SVZ-neurons, M-neurons and human iPSCs) were
supplemented with a mixture (referred to as α5) composed of essential
amino acids, TCA intermediates and co-factors (produced by
Professional Dietetics, Italy). The mixture was added at 0.5 % (w/vol)
to achieve final medium concentration as follows: histidine (0.10 mM),
isoleucine (0.40 mM), leucine (1.19 mM), lysine (0.58 mM), methio-
nine (30 μM), phenylalanine (60 μM), threonine (0.30 mM), tryptophan
(50 μM), valine (0.44 mM), cysteine (0.13 mM), tyrosine (20 μM),
thiamine (75 nM), pyridoxine (112 nM) citric acid (0.21 mM), malic
acid (70 μM) and succinic acid (80 μM) (Table S1). For comparison, we
tested the α1 mixture 0.5 % (w/vol) having the same composition of
α5, with the exception of TCA intermediates (citric, malic and succinic
acid) (Table S1). To determine whether the differentiation action of
these mixtures was due to their specific amino acid composition, we
generated another formula with a mixture of free amino acids designed
on the amino acid profile of casein, the principal protein component of
rodent diets. This mixture (referred to as Cas, Table S1) was added at
0.5 % (w/vol) concentration. Medium pH was adjusted at 7.4 and then
Cas, α1 or α5 containing-media were filtered before being added to the
specific cell culture condition. All media were changed every 2–3 days
for the entire differentiation protocol (DIV 10).
2.4.1. Rapamycin/DMSO administration
The differentiation medium of α5-treated PDGFRβ+ meningeal
NSCs was supplemented with 50 nM rapamycin or DMSO for 10 DIV
[32]. As control, untreated PDGFRβ+ meningeal NSCs receive in the
differentiation medium only DMSO for the same period. Cell medium
was changed every 2–3 days for the entire treatment period.
2.5. Proliferation
Proliferation was quantified by incubating cells for 2 hours with 1
mCi/mL [3 H]-thymidine. Thereafter, cells were fixed with 100 %
ethanol for 15 min at 4 °C, precipitated with 10 % trichloroacetic acid
and lysed with 0.1 N NaOH. The amount of [3 H]-thymidine in-
corporated into DNA was measured by scintillation counting.
2.6. Metabolic flux assays
Matabolic flux assays of glycolysis, glucose and glutamine were
done as previously described [33] by using radiolabeled tracers: 0.4
mCi/mL [5-3H]-D-glucose (PerkinElmer), 0.55 mCi/mL [6-14C]-D-
Glucose, 0.5 mCi/mL [U-14C]-glutamine.
2.7. Global transcriptomic (RNA Sequencing)
RNA from meningeal and SVZ neuronal differentiating cell (DIV 5)
was extracted with TRIzol (Life Technologies). RNA quality control was
performed with the Agilent 2200 Tape Station system and only RNAs
with a RIN > 8 were used for library preparation. Libraries for mRNA
sequencing were prepared starting from 7 ng tot RNA for each sample
by using the SMART-Seq v4 Ultra Low Input RNA Kit (Clontech-
Takara). The SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing
incorporates SMART® (Switching Mechanism at 5′ End of RNA
Template) technology. This technology relies on the template switching
activity of reverse transcriptase to enrich for full-length cDNAs and to
add defined PCR adapters directly to both ends of the first-strand cDNA
[34]. This ensures that the final cDNA libraries contain the 5′ end of the
mRNA and maintain a true representation of the original mRNA tran-
scripts. All samples were sequenced with the Illumina NextSeq 500 at
an average of 27 million 75-bp single-end reads.
Quality of raw reads was checked with FASTQC [35]. The raw se-
quenced reads were mapped according to the mouse reference tran-
scriptome and genome (Genecode Release M20 (GRCm38.p6)) using
STAR-2.5.3a [36]. Mapped reads were assigned to Ensemble gene IDs
with feature Counts 1.6.0 [37]. Counts were imported to the Bio-
conductor package DESeq2 1.22.2 and normalized using the vst function
[37]. Differentially expressed genes were identified with a model that
takes into account the different cell lines. Gene ontology and pathway
enrichment analyses were performed with Enrichr web server [38]
keeping up- and downregulated genes separate and considering a cut-
off for FDR < 0.05. Gene set variation analysis was performed on log2
normalized counts with the GSVA Bioconductor package 1.30.0 using
custom gene sets [39]. Heatmaps were generated with the Bioconductor
package ComplexHeatmaps 1.20.0. The NRF2 pathway was downloaded
from WikiPathways [40] and annotated using Cytoscape [41]. Unless
indicated, all the p-values refer to Wilcoxon rank-sum test.
2.8. Immunofluorescence
Cells were plated onto poly-D-lysine coated glass slides and the
staining procedure was performed as previously described [42]. Briefly,
following fixation in 4% paraformaldehyde (PFA, [Sigma-Aldrich]),
non-specific binding sites were blocked by incubation in a blocking
solution (3% fetal bovine serum, 3% bovine serum albumin, 0.3 %
Triton X-100 in PBS). Cells were incubated in a primary antibody so-
lution for 1.5 hours at room temperature, washed three times with
blocking solution and incubated in the proper secondary antibody so-
lution for 1 hour. After three washes in blocking solution, slides were
incubated for 10 minutes with the nuclear dye TO-PRO3 [Thermo
Fisher Scientific] and mounted on glass microscope slides for confocal
microscope quantification (Zeiss LSM 710 confocal microscope) [Carl
Zeiss, Munich, Germany].
Primary antibodies: anti-MAP2 (rabbit, 1:200, M3696 [Sigma-
Aldrich]), anti-TOMM20 (mouse, 1:200, ab56783 [Abcam]), anti-
Synaptophysin (guinea pig, 1:200, 101 004 [Synaptic System]), anti-
HB9 (rabbit 1:500 PA5-23407 [Invitrogen]), anti-Desmin (anti rabbit
PA5-17182 [Invitrogen]), anti-AFP (mouse 1:500 MAB1369 [R&D sy-
tems]), anti-AP (mouse ab109489 [Abcam]), anti-ßIIITub (mouse 1:500
T8578 [Sigma]), anti-TRA1-60 (rabbit 1:500 41-1000[Invitrogen]),
anti-SSEA-4 (mouse, 1:200 ab16287 [Abcam])
2.9. Extracellular flux analysis
Oxygen consumption rate (OCR) and Extracellular Acidification
Rate (ECAR) were measured in adherent SVZ-neurons, M-neurons and
human iPSCs with a Seahorse XFe24 Extracellular Flux Analyzer
(Agilent Technologies, Santa Clara, CA). Cells were seeded at a density
of 6 × 10 [5] cells/well in a XFe24-well cell culture microplate coated
with poly-D-lysine and cultured in a 37 °C incubator with humidified 5%
CO2 atmosphere for 10 days in neural differentiation protocol. The
Seahorse XF DMEM Medium (Seahorse Bioscience, cat. No. 102353-
100) used to perform the assay, was supplemented with 25 mM Glu-
cose, 1 mM Sodium Pyruvate and 2 mM Glutamine, at a pH of 7.4. OCR
and ECAR were measured at baseline and after sequentially adding 1
μM oligomycin A, 1 μM of carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP) and 1 μM of Rotenone and Antimycin A. The
detailed protocol was as follows: Basal OCR: 3 cycles; each cycle con-
sisting of 3′ Mixing, 2′ waiting and 3′ Recording; Oligomycin addition
through port A: 3 cycles; each cycle consisting of 3′ Mixing, 2′ waiting
and 3′ Recording; FCCP addition through port B: 3 cycles; each cycle
consisting of 3′ Mixing, 2′ waiting and 3′ Recording; Rotenone and
Antimycin addition through port C: 3 cycles; each cycle consisting of 3′
Mixing, 2′ waiting and 3′ Recording. Data was calculated as follows:
Basal Respiration: OCRBASAL – ORCROT.ANT; Maximum respiratory ca-
pacity: OCRFCCP - ORCROT.ANT; ATP production (Oligomycin-sensitive
respiration): OCRBASAL – OCROLIGO. Spare Respiratory Capacity:
OCRFCCP - OCRBASAL. Since the inhibition of glycolysis by 2-deoxy-
glucose was not performed, the basal ECAR data (ECARBASAL, before
oligomycin injection) could not be cleared from non-glycolytic
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acidification; therefore, ECARBASAL was considered and discussed as an
index comprising glycolysis and CO2-related acidification derived from
the TCA cycle, the latter contributing up to the 42 % of the ECAR in
neural stem cells culture [43]. The injection of oligomycin inhibits
mitochondrial ATP production, and shifts the energy production to
glycolysis. As such, the Glycolytic Reserve, calculated as ECAROLIGO –
ECARBASAL was considered as pure glycolytic index because not affected
by the background. Data were normalized to the DNA content per well
that was quantified with the CyQUANT Cell proliferation assay kit
(Thermo Fisher Scientific, cat. No. C35007), according to the manu-
facturer’s instructions.
2.10. Immunoblot analysis
Immunoblot analysis was performed as previously described [44].
Briefly, whole proteins were extracted in RIPA buffer (Cell Signaling,
#9806) and quantified using the Bicinchoninic Acid (BCA) Assay
(Thermo Scientific). Samples were separated by 4–20 % SDS-PAGE and
electroblotted on PVDF membranes for immunodetection. After
blocking, the membranes were probed by the appropriately diluted
primary antibodies overnight at +4 °C and subsequently incubated
with horseradish peroxidase-conjugated secondary antibodies for 2 h at
room temperature. Immunoblots were developed using the ECL system.
Chemiluminescence-based immunostaining (ECL kit, Amersham) was
performed using the following antibodies: anti-α-Tubulin 1:2000 (Santa
Cruz Biotechnology, #sc-23948); anti-GAPDH 1:10000 (Abcam #
ab8245); anti-DRP1 (Abcam # ab56788) at 1:1000 dilution; anti-MFN2
(Abcam # ab56889) at 1:1000 dilution; anti-OPA1 (BD Biosciences
#622607) at 1:1000 dilution; anti-Phospho-P70S6K (Cell Signaling
#9205); anti-P70S6K (Cell Signaling #9202), anti-VDAC1 (Abcam
#ab14734) at 1:1000 dilution; Total OXPHOS Rodent WB Antibody
Cocktail (Abcam #ab110413) at 1:1000 dilution; anti-PITRM1 (Atlas
#HPA006753) at 1:1000 dilution; anti-SIRT1 (Cell Signaling Tech-
nology #2028S) at 1:1000 dilution; anti-PGC-1α (Novus Biological,
#NBP1-04676) at 1:1000 dilution. Secondary antibodies conjugated
with HRP were from Invitrogen or Santa Cruz Biotechnology and used
at 1:5000 dilution. Images were acquired with the use of ChemiDoc
Imaging System apparatus (Bio-Rad Laboratories, Milan, Italy) and
analysed with Image Lab™ software, version 6.0.1 for Windows (Bio-
Rad Laboratories, Milan, Italy).
2.11. Protein synthesis (WB-SUnSET)
Protein synthesis in controls and α5 treated SVZ- and M-neurons
was measured using Puromycin Dihydrochloride (Gene Spin). Briefly,
cells were plated in a 24-well plate and loaded with Puromycin
Dihydrochloride (1ug/mL) for 10 minutes at 37 °C, 5% CO2. Afterward,
cells were lysed in RIPA Buffer with phosphatase and protease in-
hibitors and Western Blot analysis was performed with Ab anti-pur-
omycin (Millipore, MAEBE434) on the cell lysates.
2.12. Image analyses and quantification
To evaluate the neuronal differentiation for each α5 condition, we
performed immunofluorescence as described above. For every analysis
described, quantifications were done with NIH ImageJ software [U.S.
National Institutes of Health] [44]. The positive-immunoreactive cells
for each marker were determined using the ImageJ software. Data was
expressed as percentage of positive cells/ total number of counted (TO-
PRO3+) cells. Images were acquired using a 100x oil objective [Carl
Zeiss, Munich, Germany], with a 1024 × 1024 resolution, acquisition
speed 7, and are maximum intensity projection images of 5–10 z-stack
images (0.75 μm depth).
2.12.1. Neuronal morphology
Neuronal dendrites were analysed and quantified in blind by at least
two independent observers using a custom-designed ImageJ plugin
[U.S. National Institutes of Health]. Evaluation was performed on cells
immunoreactive for MAP2 staining, which allowed for visible identifi-
cation of neuronal dendrites. Data were expressed as mean number of
branches/ MAP2+ cell, total dendrite length/ MAP2+ cell and mean
branch length/ MAP2+ cell. Dendritic spines were counted using a
custom-designed ImageJ plugin [U.S. National Institutes of Health] and
dendritic spine morphology analysis was performed using the Neuron
Studio software [45]. Data was expressed as number/ type of spines/
100 μm MAP2+ dendrite.
M-neurons treated with α5/rapamycin or α5/DMSO or DMSO were
immunostained, as previously described, with MAP2 and DAPI and
quantified in blind by at least two independent observers. Using ImageJ
(U.S. National Institutes of Health) the total MAP2+ branch area was
evaluated. The mean area of branches was obtained as ratio between
the total MAP2+ branch area and the total number of MAP2+ cells. At
least 125 images per condition were analized in 3 independent ex-
periments for a total of 375 images analyzed.
2.12.2. Synaptic puncta quantification
Immunoreactive Synaptophysin puncta were counted in blind by at
least two independent observers using the SynapseCount [46] ImageJ
plugin [U.S. National Institutes of Health].
2.12.3. Neuronal differentiation in motor neurons
ßIII-tubulin (Tub3) expression was analysed and quantified in blind
by at least two independent observers using ImageJ plugin [U.S.
National Institutes of Health]. Total nuclei were counted using a
custom-designed ImageJ plugin [U.S. National Institutes of Health].
Data were expressed as percentage Tub3+ area/ total nuclei.
2.12.4. Mitochondrial area
Mitochondrial area was measured as TOMM20+ area/total MAP2+
area as previously described [33]. Neuronal mitochondria were counted
in blind quantification by at least two independent observers using a
custom-designed ImageJ plugin [U.S. National Institutes of Health].
2.12.5. Mitochondrial morphology analysis
At least 24 stacks of 0.75 μm each were acquired for each type of
cell using a Zeiss LSM710 confocal microscope equipped with the 100×
objective (for SVZ- and M-neurons) or with the 63X objective (for
human cells). A region of interest (ROI) delimiting each single dendrite
analysed from max projection images was selected. Images were then
processed using a custom-designed ImageJ macro [U.S. National
Institutes of Health] in order to obtain mitochondrial morphology data
(number of fragmented, short and long mitochondria, mitochondrial
area and perimeter). We classified mitochondria as “fragmented” when
mitochondria were spherical (major axis equal to minor axis); “inter-
mediate” when mitochondria presented a major axis less than ∼2 μm
M- and SVZ-neurons or ∼10 μm for human cells; “elongated” were
mitochondria in which the major axis was more than ∼2 μm for SVZ-
and M-neurons or ∼10 μm for human cells [47,48]. “Fused” mi-
tochondria were defined on the base of their interconnectivity score
that describe the network of the mitochondria. This parameter was
calculated by dividing the mean mitochondria area by the mean mi-
tochondrial perimeter of all the particles analysed in the dendrite
considered [49]. Higher score for interconnectivity means higher mi-
tochondrial “fusion”. For SVZ- and M-neurons, at least 26 or 33 cells per
condition were analysed respectively in at least 5 independent experi-
ments for a total of 318 dendrites (for SVZ-neurons: total number
analysed mitochondria: 2796; for M-neurons: total number analysed
mitochondria: 2348). For human cells at least 24 cells per condition
were analysed in at least 3 independent experiments for a total of 141
dendrites (total number analysed mitochondria: 2797).
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2.13. Oxidative stress analysis
ROS scavenging in 2,3-Dimethoxy-1,4-naphthoquinone (DMNQ)
treated cells was measured using 5-(6)-chloromethyl-2′,7′-di-
chlorodihydrofluorescein diacetate (CM-H2DCFDA, Cayman Chemical)
as previously described. Briefly, cells were plated in a black 96-well
microplate and loaded for 30 min at 37 °C in the dark with CM-
H2DCFDA (10 μM). Afterwards, cells were exposed to DMNQ (50 μM)
and fluorescence was assessed with a multi-plate reader with excitation
and emission wavelengths of 485 and 530 nm, respectively (Victor™,
PerkinElmer, Waltham, MA, USA).
2.14. Statistical analysis
As described for each methodology, n≥5 independent experiments
each group with at least n≥3 technical replicates were used for
(caption on next page)
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statistical analysis. Differences between experimental conditions were
analysed using unpaired t-test or one-way ANOVA’s followed by a
Tukey post-test. A p value <0.05 was considered statistically sig-
nificant. When different test was used, detailed description has been
provided in the figure legends.
3. Results
3.1. Branched-chain amino acid treatment drives persistent metabolic shift
to energy metabolism in differentiating neurons
A shift towards oxidative phosphorylation is required during SVZ-
NSC neuronal differentiation [7]. To induce complete neuronal differ-
entiation, we propose to obtain a persistent oxidative metabolism shift
in differentiating neurons. Therefore, optimal combination of relevant
metabolic precursors, known to increase oxidative metabolism, was
evaluated. Specifically, we tested the effect of branched-chain amino
acids, essential amino acids, TCA precursors, and cofactors on differ-
entiating SVZ-NSCs (Table S1). Branched-chain amino acids such as
leucine, isoleucine and valine, share the first enzymatic steps in their
metabolic pathways that lead to an irreversible oxidative decarbox-
ylation to coenzyme-A derivatives, thus entering the Krebs cycle and
promoting oxidative phosphorylation [50]. Similarly, other amino acids
like tyrosine, lysine, phenylalanine and tryptophan are metabolised to
Acetyl-CoA [51]. In addition, citrate, malate and succinate act via direct
support of the Krebs cycle being relevant intermediates, and succinate
also feeds the electrons to mitochondrial complex II [52], thereby
sustaining oxidative phosphorylation. We treated for 6 days differ-
entiating neurons with: a control casein-amino acid mixture (referred to
as Cas), in which amino acids composition was that of casein; and a
specific mixture of essential amino acids enriched in branched-chain
amino acids, previously shown to increase mitochondrial function and
activate mTORC1 complex (referred to as α1) (16) with the addition of
TCA precursors, and cofactors (referred to as α5) (see Material and
Methods). Notably, the addition of α5 maximally increased the OCR of
differentiating neurons (Fig. S1A, B). Administration of either in-
dividual substrates or the mixture of essential amino acids without the
TCA precursor and cofactors (α1) was less effective in increasing the
OCR of differentiating neurons (Fig. S1A, B and data not shown). To
better highlight the overall metabolic profile of the differentiating
neurons, we create an Energy map (see Fig. S1C) represented as com-
bination of the variation (z-score) of extracellular acidification rate
(ECAR), an indirect measure of glycolysis, and of the oxygen con-
sumption rate (OCR). Notably, the α5 mixture maximally increased the
overall basal energy metabolism of the differentiating neurons (Fig.
S1C).
To test whether the effect of α5 on the oxidative phosphorylation
increase was not restricted to SVZ derived neurons (SVZ-neurons), but
applicable more generally for stem cell differentiating into neurons, we
tested α5 treatment in another NSC source. We recently identified
neurogenic NSCs in meninges (M-NSCs) [14,26,29]. M-NSCs showed
comparable transcriptomic signature with SVZ-NSCs [14]. However,
the metabolic profile of M-NSCs and of M-NSC derived neurons (M-
neurons) has never been assessed. We, therefore, performed metabolic
flux analysis in M-NSCs and M-neurons (Fig. 1A–D). As expected, si-
milarly to SVZ-neurons [7], we found a metabolic switch with a de-
crease in glycolysis and an increase in oxidative phosphorylation in M-
neurons compared to M-NSCs (Fig. 1B–D).
To test the effect of α5 on neuronal differentiation, we added α5 to
SVZ- and M- NSCs for the entire differentiation protocol (day in vitro,
DIV 10) and we measured the energy metabolism of the differentiated
neurons. At DIV 10, we observed a significant increase of basal oxygen
consumption rate in SVZ-neurons and M-neurons (Fig. 1E–H). Accord-
ingly, ATP production was increased in both SVZ-neurons and M-neu-
rons exposed to α5 compared to untreated cells (Fig. 1I). We assessed
the overall metabolic profile of SVZ- and M- differentiated neurons by
the Energy map (see Fig. 1J). Following α5 administration, SVZ- and M-
neurons shift in the upper left quadrant of the energy plot, indicating a
more oxidative metabolism compared to untreated cells (Fig. 1J).
We further measured the capability of differentiating neurons to
adapt their cell metabolism following metabolic stress, including the
inhibition of ATP synthases (oligomycin) and the depolarisation of the
inner mitochondrial membrane (FCCP). Hence, we analysed the max-
imal glycolytic and OXPHOS metabolic capabilities in terms of re-
spiration arrest-induced maximal glycolytic rates (i.e., glycolytic re-
serve) and depolarisation-induced maximal OXPHOS rate (i.e., spare
respiratory capacity and maximal respiration). Treatment with α5 in-
stigated a significant increase of the maximal OXPHOS capabilities in
both SVZ- and M-neurons as assessed by maximal respiration rate
(Fig. 1H) and spare respiratory capacity (Fig. 1K). Furthermore, α5
treated neurons showed a significantly improved glycolytic reserve
(Fig. 1L). According to these data, α5 treated neurons appear to have
higher energetic reservoir to cope with metabolic stress conditions,
highlighting their increased metabolic plasticity (Fig. 1J).
Overall, these data indicate that α5 administration increased the
energy metabolism and the metabolic plasticity in differentiating neu-
rons.
3.2. Branched-chain amino acids-driven metabolic shift induces complete
neuronal differentiation of both SVZ- and M- NSCs
Neuronal differentiated cells greatly modify their cellular mor-
phology expanding dendrite and axonal branching and budding den-
dritic spines. To test our hypothesis that a branched-chain driven me-
tabolic shift enhances NSC neuronal differentiation, we firstly evaluated
changes in neuronal morphology of differentiated cells. At 10 DIV of
neuronal differentiation, we analysed the morphology of the MAP2+
differentiated cells in control and α5 conditions. Although we did not
observe increase number of differentiated neurons (data not shown), we
observed a statistical increase of mean branching number, mean and
the total branch length in both α5-treated SVZ- and M- neurons
(Fig. 2A–D). Dose response experiments by using α5 at 0.1 %, 0.5 % and
1% (w/vol) dilution, further indicated that the dilution of 0.5 % more
efficiently increase the neuronal morphology in both differentiating
Fig. 1. α5 induces persistent oxidative metabolic shift in differentiating NSCs.
(A) Proliferation analysis evaluated by 3H thymidine incorporation in M-NSCs and M-neurons showing decreased proliferation in M-neurons compared to M-NSCs.
(B–D) Metabolic flux analysis in M-NSCs and M-neurons showing decreased glycolysis and increased glucose and glutamine oxidation in M-neurons compared to M-
NSCs. For (A–D) n = 6 independent experiments for each group (M-NSCs and M-neurons) were considered and at least 3 technical replicates for each n were
considered. (E,F) Representative graph of OCR analysis showing that both SVZ-neurons (10 DIV) and M-neurons (10 DIV) supplemented with α5 (green line for SVZ-
neurons and red line for M-neurons) display higher respiration rate compared to controls (dashed grey lines). (G–I) Quantitative analysis of OCR parameters in SVZ-
neurons and M-neurons showing that α5 supplemented neurons display a higher basal (G), maximal respiration (H) and ATP production (I). (J–L) Energy maps of the
SVZ-neurons (green/grey square) and M-neurons (red/grey circle), representing basal metabolic rate and metabolic response after the inhibition of the ATP synthase
with oligomycin and the administration of mitochondrial uncoupler FCCP. α5-treated cells are more poised to rely on aerobic metabolism at the basal state, have
higher spare respiratory capacity (K) and glycolytic compensation (i.e., glycolytic reserve) (L) in response to oligomycin and FCCP, compared to CRL cells. Data are
extrapolated from the Mitostress test; For (G–L) n≥6 independent experiments for each group (SVZ-neurons CRL, SVZ-neurons α5, M-neurons CRL and M-neurons
α5) and 4 technical replicates for each n were considered. Data are presented as mean ± SEM. *=p< 0.05; **=p< 0.01; ***=p< 0.001. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article).
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SVZ- and M- neurons (Fig. S2A–D). Therefore, we selected this dilution
for all the experiments we performed (see Material and Methods for
mixture concentration). The improved neuronal differentiation was also
confirmed by the increase of MAP2+ expression in α5 treated neuronal
populations (Fig. S2E, F).
To further characterize the increased neuronal differentiation of α5
treated neurons, we evaluated synapse number and morphology.
Synaptophysin is a synaptic vesicle protein ubiquitously expressed in
every neuron and the measure of Synaptophysin immunoreactive
puncta has been considered as an estimation of synapse numbers [53].
In line with the increased complexity of neuronal branching, we found
that the number of Synaptophysin immunoreactive puncta increased in
α5 treated neurons compared to the controls (202.4 ± 9.9 vs 374.7 ±
23.7 and 194.0 ± 14,0 vs 245.8 ± 11.7 in SVZ and M-neurons, re-
spectively, p < 0.05; Fig. 2E, F). Dendritic spines are micron-sized
protrusions along the dendritic shaft that are composed of a spine head
and a thin spine neck that connects them to the dendritic shaft [54].
Based on their morphology, three shape categories have been defined:
thin, filopodia-like protrusions (“thin spines”), short spines without a
well-defined spine neck (“stubby spines”) and spines with a large bul-
bous head (“mushroom spines”) [55]. Spine number and morphology
are correlated to neuronal maturation [55]. Stubby and mushroom
spines increase in fully differentiated neuronal cells [55]. We found a
statistically significant increase of the fraction of more mature stubby
and mushroom spines in α5 treated neurons compared to the control
(Fig. 2H, S2G). The acquisition of a more stable spine morphology (i.e.,
stubby and mushroom), further indicated that α5 treatment increased
neuronal differentiation.
Overall, morphological and protein expression analysis showed that
α5 treatment improved neuronal differentiation.
Global transcriptomic analysis highlights the increase in expression
of oxidative phosphorylation and neural differentiation genes in α5
treated SVZ- and M-neurons
To further investigate α5 effect on neuronal metabolism and dif-
ferentiation, we analysed the signature of differentiating neurons in
control and α5 conditions by global transcriptomics (RNA sequencing)
(Fig. 3A–D). Principal component analysis (PCA) of the RNA sequencing
data confirmed that differentiated neurons treated with α5 were a se-
parate population in particular on the first principal component
(Fig. 3A). Transcriptomic analysis indicated that the most significant
up-regulated genes in α5 treated populations were related to the Gene
Ontology categories mitochondrial function, including the mitochon-
drial matrix, membrane, outer membrane and ribosomes, and neuronal
differentiation, including the synapse, synapse part, synaptic and
postsynaptic membrane (Fig. 3C). In particular, GSVA (Gene Set Var-
iation Analysis) showed that α5 treated cells decreased the expression
of undifferentiated genes (i.e. nestin, pax6, fabp7) and increased the
expression of the neural differentiating ones (i.e. tubb3, dcx, map4)
(Fig. 3D). In line with the improved neuronal differentiation of α5
treated populations, transcriptomic data confirmed the decreased ex-
pression of genes related to glycolysis (i.e. hif1a, pfkfb3) while an
overall increased transcription in gene related to oxidative metabolism
(i.e. Sdha, Sdhb, Sucla2, Rpia, H6pd, Prps1 and 2, Atp5s, Atp5b, Rpe, Pgd,
Pgls, Fh1, Idh2, Ogdh) (Fig. 3B).
Overall, complementary approaches indicated that α5 treatment
increased the oxidative metabolism and improved neuronal differ-
entiation, as shown by increased branching, distribution of the synaptic
marker and presence of morphologically more mature spines.
3.3. Branched-chain amino acids-driven metabolic shift activates mTORC1
and increases mitochondrial fusion in differentiated neurons
Neurons increase their cellular energy requirement to satisfy all the
anabolic needs related to neuronal differentiation, including protein
and membrane synthesis. Conditions of increased cellular nutrients (i.e.
leucine) and energy availability (i.e. ATP content) are known to inhibit
the AMPK, a major mTORC1 inhibitor that mediates catabolic path-
ways, and to increase mTORC1 activity, which plays a central role in
regulating the anabolic processes [20,56]. During neuronal differ-
entiation, mTORC1 complex activation promotes neural stem cell dif-
ferentiation [11,57,58], whereas sustained activation of mTORC1 leads
to a reduction of proliferative NSC in the SVZ [59]. Therefore, we as-
sessed whether the branched-chain amino acids-driven metabolic shift,
which increased energy metabolism, ATP production and neuronal
differentiation, was associated with an increase of mTORC1 dependent
anabolism. Western blot analysis revealed that α5 treated SVZ-neurons
increased mTORC1 serine/threonine protein kinase expression and the
phosphorylation of its substrate p70S6 Kinase 1 (S6 K1; Fig. 4A). As
further confirmation of the anabolic effect of mTORC1/S6 K1 signal-
ling, we found that α5 treated neurons had increased overall protein
synthesis (Fig. 4B) and expression of genes involved in mitochondrial
protein translation (Fig. 4C). To assess whether neuronal differentiation
requires activation of mTORC1/S6 K1 anabolism, we administrated a
low dose of the mTOR inhibitor rapamycin (50 nM) [32] and found that
rapamycin treatment abolished the effect of the α5 on increasing neu-
ronal differentiation (Fig. 4D).
To assess whether the metabolic shift to energy metabolism ob-
served in α5 treated neurons was related to an increase of mitochon-
drial mass, we performed quantification of mitochondrial DNA (Fig. 4E)
and expression of constitutive mitochondrial proteins (Fig. 4F–I). The
amount of mitochondrial DNA (mtDNA) was not affected by the α5
treatment (Fig. 4E). In line with this, we didn’t detect an increase of the
amount of proteins related to mitochondrial biogenesis pathway PGC-
1α and of its upstream regulator SIRT1 [60] (Fig. 4F). Accordingly, the
amount of mitochondrial respiratory chain subunits, both nuclear-
(UQCRC2, ATP5A) and mitochondrially-encoded (MT-COI) were un-
changed upon α5 supplementation (Fig. 4F). Moreover, mitochondrial
proteins of the outer mitochondrial membrane (VDAC1) and of the
matrix (PITRM1) [61], were also unchanged in α5-treated neurons
(Fig. 4F). Altogether, these data indicated that the shift towards energy
metabolism was not due to an increase of mitochondrial mass or of the
level of mitochondrial respiratory chain enzymes.
Fig. 2. α5 increases neuronal differentiation of NSCs in vitro.
(A) Representative pictures of MAP2+ SVZ-neurons and M-neurons at 10 DIV in control and α5 condition showing that α5 treated neurons display more ramified
dendrites. In the white panel representative skeleton analysis of the neuronal branching. (B–D) Quantitative analysis of the number, medium length and total length
of SVZ-neuron and M-neuron dendrites showing that MAP2+ α5 treated neurons statistically increases the number, the medium length and the total length of
branches in both populations. n = 6 independent experiments for each group were considered and at least 10 technical replicates for each n were considered. (E)
Representative pictures of the expression of Synaptophysin immunoreactive puncta in SVZ-neurons and M-neurons in control and α5 treated samples. (F)
Quantitative analysis showing that α5 treated neurons express more Synaptophysin+ immunoreactive puncta compare to control neurons. n = 6 independent
experiments for each group were considered and 3 technical replicates for each n were considered. (G) Representative images of SVZ-neuron and M-neuron MAP2+
dendritic spines of different morphology in control and α5 treated neurons. Blue arrowheads indicate thin spines, green arrowheads indicate stubby spines, while red
arrowheads indicate mushroom spines. (H) Quantitative analysis showing that supplemented SVZ-neurons have more mushroom spines and supplemented M-
neurons have more stubby spines, compared to the control. Quantification is represented as fold increase of specific dendritic spine type on the control (n≥6
independent experiments for each group, at least 120 spines/cell for 5 cells each experiment were considered). Images in panels (E,G) are maximum intensity
projection of confocal z-stacks images. Scale bars: 50 μm. Data are presented as mean ± SEM. *=p < 0.05; **=p< 0.01; ***=p< 0.001. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article).
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Differentiating neurons have a particular dependence on precise
control of mitochondrial fission and fusion dynamics [62,63]. To fully
sustain the metabolic shift towards oxidative phosphorylation, den-
dritic outgrowth, spine formation, and cell survival, differentiating
neurons increase their mitochondrial fusion [62,64]. Elongated mi-
tochondria are associated with increased oxidative phosphorylation
(OXPHOS) activity and ATP production [65,66]. We, therefore, as-
sessed the mitochondrial dynamic in differentiated neurons. Dynamin-
Fig. 3. Global transcriptome analysis shows that α5 increasesoxidative metabolism and neuronal differentiation genes.
(A) Principal component analysis (PCA) of the RNA sequencing of α5 treated and untreated cell population showing that α5 treated M-neurons and SVZ-neurons
(yellow ellipse) cluster together and separately from control untreated M-neurons and SVZ-neurons (grey ellipse) (8 different pool of cells were analysed). (B)
Heatmap of gene expression highlights the presence of two clusters untreated and treated (framed by black line). The colours in the horizontal bar above the cluster
colour bar indicate the nature of the analysed cells treated (orange) or untreated (grey); for the complete list of signature genes, see Table S2. The scaled normalized
expression levels of neural stem cell, glycolysis, neural differentiation and oxidative phosphorylation genes is shown. (C) Cellular component Gene Ontology analysis
showing that up-regulated genes in the α5 treated neurons are related to mitochondrial function, including the mitochondrial matrix, membrane, outer membrane
and ribosomes and neuronal differentiation, including the synapse, synapse part, synaptic and postsynaptic membrane. (D) GSVA (Gene Set Variation Analysis) test
shows a decreased expression of neural stem cell and glycolysis gene-sets after α5 treatment, while an increased expression of neural differentiation and oxidative
metabolism gene-sets. For the complete list of signature genes, see Table S2. For each condition CRL and α5. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article).
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related protein 1 (Drp1) mediates mitochondrial fission, while Mito-
fusin 2 (Mfn2) and Optic Atrophy 1 (Opa1) [67–69] are the main reg-
ulators of mitochondrial fusion in neurons [70]. We then analysed the
effect of α5 treatment on Drp1, Mfn2 and Opa1 protein expression in
differentiating neurons. Treatment with α5 induced a decrease (0.83 ±
0.6.4 and 0.73 ± 0.33; p < 0.001 and p < 0.05 in SVZ- and M-neurons
respectively) of DRP1 and an increase of MFN2 (2.69 ± 0.49 and 7.3 ±
2.2; p < 0.05 in SVZ- and M-neurons respectively) and OPA1 (5.78 ±
1.8 and 6.6 ± 1.6; p < 0.01 and p < 0.05 in SVZ- and M-neurons
respectively) protein expression, suggesting an increase in mitochon-
drial fusion events (Fig. 4G, I). Mitochondrial network and organelle
lengths are determined by the balance between fission and fusion.
(caption on next page)
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Mitochondrial morphologies can change dramatically by shifting this
balance [71]. Our data indicated a significant upregulation in the total
amount of OPA1 and MFN2 analysed in treated SVZ- and M- neurons; in
particular, both long and short Opa1 isoforms were increased compared
to untreated neurons (Fig. 4G, I). Since OPA1 long forms support mi-
tochondrial fusion, whereas the short forms are better able to restore
energetic efficiency [72], our data, together with the increase of MFN2,
supported the idea that α5 supplementation is able to modulate mi-
tochondrial dynamics through a shift to pro-fusion events in response to
metabolic stimuli. Moreover, the upregulation of OPA1 and MFN2 was
paralleled by a significant drop in the total amount of DRP1 upon α5
supplementation (Fig. 4G, I). Although we did not check neither the
DRP1 localisation nor the phosphorylation status, the substantial de-
crease of DRP1 strongly suggested that the treatment with the α5
mixture also caused a downregulation of mitochondrial fission events.
Therefore, we analysed the mitochondrial network (Fig. 4J–Q). Quan-
titative analysis showed that α5 treated neurons increased the mi-
tochondrial length (Fig. 4K, L, O, P) and the mitochondrial fusion index
calculated as interconnectivity score (Fig. 4M, Q) [49]. These data
suggested that α5 promoted the formation of networks of elongated
mitochondria in neuronal dendrites compared to the dispersed dis-
tribution of punctate mitochondria observed in control neurons
(Fig. 4J–Q).
Overall, these data indicated that α5 treatment increased anabo-
lism, mTORC1 activity and mitochondrial fusion in differentiating
neurons associated with the increase of energy metabolism.
3.4. Branched-chain amino acids-driven metabolic shift increases
antioxidant defence in differentiated neurons
Transcriptomic analysis highlighted that α5 treated cells, in addi-
tion to enhance neuronal differentiation, up-regulated the antioxidant
related genes (Fig. 5A, B). Reactive oxygen species (ROS) are naturally
produced by several metabolic reactions, most notably as a by-product
of the ATP synthesis in mitochondria, and the management of the levels
are important for cellular homeostasis [73,74]. Neurons, which greatly
use oxidative metabolism, require proper antioxidant defences.
Interestingly, the analysis of Gene Ontology enrichment for the mole-
cular functions categories revealed that the most enriched activities of
α5 treated samples were related to antioxidant activity (Fig. 5B).
Likewise, an increased gene expression of relevant enzymes involved in
antioxidant defence, including superoxide dismutase (sod2), heme
oxygenase-1 (hmox1) glutathione synthase (gss) oxidase (gpx1, gpx4,
gpx8) and reductase (gsr), was observed in α5 treated neurons (Fig. 5C).
In accordance, a pathway analysis investigation, using WikiPathways
library, further confirmed up-regulation of two critical pathways in-
volved in antioxidant activity, such as glutathione metabolism and the
NRF2 pathway (Fig. 5A, D). To further confirm that α5 treated neurons
increased ROS scavenging mechanisms, we tested their antioxidant
activity at functional level. When ROS levels were measured by CM-
H2DCFDA labelling following the treatment with the ROS inducer
DMNQ, α5 treated neurons shown a reduced increase in CM-H2DCFDA
fluorescence intensity (Fig. 5E, F), implying an accelerated ROS de-
toxification. These data indicate that α5 treatment induces antioxidant
properties in differentiating neurons.
3.5. Branched-chain amino acids-driven persistent oxidative metabolic shift
increases mitochondrial elongation and neural differentiation in human
iPSCs
The effect of branched-chain amino acids-driven increasing energy
metabolism and neuronal differentiation was obtained from mouse
NSCs of different brain regions (SVZ and meninges), suggesting that the
observed effect is not limited to a specific cell origin. To evaluate
whether the effects of branched-chain amino acids-driven metabolic
shift on both energy metabolism and neuronal differentiation were also
applicable on human neuronal cells, we tested and confirmed the re-
sults on iPSCs. Skin biopsy-derived fibroblasts were reprogrammed to
generate pluripotent cells expressing pluripotency markers (Fig. 6A, C)
and able to spontaneously differentiate into three germ layer cells
(Fig. 6B). Human iPSCs were then differentiated into motor neurons
(Fig. 6D) [31]. During the last 6 days of neuronal differentiation, we
administered α5 treatment and compared against control cells the OCR,
the energy map, the mitochondrial network and neuronal
Fig. 4. α5 treatment activates mTORC1 pathway and increases mitochondrial fusion.
(A) Representative western blot analysis of mTORC1, S6 Kinase 1 (S6 K1), p70S6 Kinase 1 (pS6 K1) of α5 treated and control (CRL) SVZ-neurons. Statistical analysis
shows that α5 treated SVZ-neurons increase the phosphorylation of mTORC1 substrate p70S6 Kinase 1 (S6 K1). For each condition CRL and α5 (n = 6 independent
experiments). (B) Puromycin incorporation detected by western blotting in control and α5 treated SVZ-neurons. The graph represents statistical analysis result
showing that protein synthesis is increased following α5 treatment (n = 6 independent experiments). (C) Schematic drawing showing the pool of mitochondrial
protein translation genes and mitochondrial protein synthesis genes that are up-regulated following α5 treatment (green up-regulated genes, orange down-regulated
genes). (D) Quantitative analysis of the MAP2+ branches area in M-neurons following the treatment with medium supplemented with α5/DMSO (-/+), or α5/
rapamycin (+/+) or only DMSO (-/-), showing that the administration of rapamycin abolishes the effect of the α5 supplementation on increasing neuronal branches.
(E) Quantification of the mitochondrial DNA copy number of SVZ-neurons and M-neurons in α5 treated and untreated conditions shows no differences in the amount
of mitochondrial DNA. (F) Western blot (WB) analysis on differentiated neurons showing that ATP5A, MT-COI, UQCRC2, PGC-1α and SIRT1 do not change in α5
treated cells compared to control. (G) Western blot (WB) analysis on differentiated neurons, showing that the mitochondrial dynamics protein, Dynamin-related
protein 1 (Drp1) mediating mitochondrial fission decreases in α5 treated differentiated neurons, while the main regulators of mitochondrial fusion Mitofusin 2
(Mfn2) and Optic Atrophy 1 (Opa1) increase in both SVZ- and M-neurons. The amount of mitochondrial proteins PTMR1, VDAC1 is unchanged. (H) The graphs show
quantitative analysis of the western blotting described in (F). (I) The graphs show quantitative analysis of the western blotting described in (G). Treated SVZ-neurons
(green bars), α5 treated M-neurons (red bars), controls (grey bars). For each condition CRL and α5, n = 6 independent experiments. (J) Representative images
showing that mitochondria of α5 treated SVZ-neurons labelled by the neuronal marker MAP2+ (red) and the green-fluorescent mitochondrial stain (mito) are fused
compare to mitochondria of untreated control (CRL). (K) Graph representing the mitochondrial length (μm) of control (grey) and α5 treated SVZ-neurons (green)
showing that α5 supplementation resulted in a significant increase of the mitochondrial length in α5 treated SVZ-neurons (0.800 μμ m ± 0.07 μ,065 μ m) compared
to control SVZ-neurons (0.503 μμ m ± 0.03 μμ m). SVZ-neurons = 156 dendrites, 2796 mitochondria; 5 independent experiments. (L) Graph representing the
percentage distribution of the mitochondrial length in control (grey) and α5 treated SVZ-neurons (green). (M) Quantitative analysis of the interconnectivity score
(fusion index) showing that it statistically increases in α5 treated SVZ-neurons compared to control (0.166 ± 0.01 μm vs 0.123 ± 0.01 μm). (N) Representative
images showing that mitochondria of α5 treated M-neurons labelled by the neuronal marker MAP2+ (red) and the green-fluorescent mitochondrial stain (mito) are
more elongated compared to mitochondria of untreated control (CRL). (O) Graph representing the mitochondrial length (μm) of control (grey) and treated M-neurons
(red) showing that α5 supplementation resulted in a significant increase of the mitochondrial length in α5 treated M-neurons (0.548 μm ± 0.04 μm μ) compared to
control M-neurons (0.380 μm μ± 0.02 μm). M-neurons = 152 dendrites, 2348 mitochondria; 6 independent experiments. (P) Graph showing the distribution of the
mitochondrial length in control (grey) and α5 treated M-neurons (red). (Q) Quantitative analysis of the interconnectivity score (fusion index) showing that it is
statistically increased in α5treated M-neurons compared to control (0.166 ± 0.02 μm vs 0.103 ± 0.01 μm). Quantitative data are described as mean ± SEM.
Statistical analysis was performed using unpaired t-tests. *=p< 0.05; **=p< 0.01; ***p < 0.001; ****p < 0.0001. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article).
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differentiation. We found that α5 treated neurons derived from human
iPSCs significantly increased their basal oxygen consumption (1.47 fold
increase, Fig. 6E, F), maximum respiration (2.2 fold increase, Fig. 6E,
G) and increased ATP production (1.34 fold increase, Fig. 6E, H). The
overall metabolic profile represented in the energy map showed higher
maximal respiration rate and spare respiratory capacity of neurons
derived from human iPSCs treated with α5 treatment compared to
control neurons (Fig. 6I, J). In this analysis no differences in glycolytic
reserve were observed between α5 treated and control iPSCs-derived
neurons (Fig. 6K).
We analysed the mitochondrial network (Fig. 6L, N–P) and we
found that α5 treated neurons derived from human iPSCs greatly in-
creased their mitochondrial area (Fig. 6L, O), the percentage of elon-
gated mitochondria (Fig. 6P) and the mitochondrial fusion index, in-
terconnectivity score (1.42 ± 0.08 control vs 1.74 ± 0.10 α5 treated
cells; p < 0.05), suggesting that α5 promoted the formation of net-
works of elongated mitochondria. Neuronal differentiating iPSCs in
culture were highly dense therefore it was not possible to identify
branch number and branch length for each cell. In order to describe the
dendrite number and extension, we measured the area of expression of
the neuronal dendrite marker ßIII-tubulin (Tub3) normalized for the
total nuclei number. We found that the area of expression of Tub3
(Fig. 6M, Q) was increased in α5 treated neurons suggesting higher
neuronal differentiation and dendrite extension.
This data indicated that α5 administration improved energy meta-
bolism, mitochondrial elongation and neuronal differentiation in
human differentiating iPSCs suggesting that α5 effect may be broad and
can be extended to human neuronal differentiation.
4. DISCUSSION
In this work, we showed that a branched-chain driven metabolic
shift enhances NSC neuronal maturation. Specifically, the administra-
tion of α5 treatment to differentiating neurons was able to increase
energy metabolism, ATP production, antioxidant defence and neuronal
maturation. Strikingly, we observed similar effect in differentiating
neurons derived from NSC of different sources: murine SVZ and brain
meninges, and human iPSCs. These observations suggested that the
branched-chain amino acids-driven modulation of energy metabolism
may be a useful approach to induce neuronal maturation, in-
dependently from the neuronal precursor origin and from differ-
entiating conditions.
In vitro and in vivo experiments have shown that neurons differ-
entiating from immature precursors require an increase of oxidative
Fig. 5. α5 treatment increases antioxidant activity.
(A) Pathway enrichment analysis with Wiki Pathways shows that critical pathways involved in antioxidant activity, including glutathione metabolism, oxidative
stress and the NRF2 pathway are up-regulated. (B) Gene Ontology of the molecular functions reveals that the most enriched activities of α5 treated samples were
related to antioxidant activity. (C) Schematic drawing of mitochondria showing that α5 treated neurons increase the gene expression of relevant mitochondrial
enzymes involved in the composition of the respiratory subunit complexes and in antioxidant defence including superoxide dismutase (sod2), heme oxygenase-1
(hmox1) glutathione synthase (gss), oxidase (gpx1, gpx4, gpx8) and reductase (gsr). In green the up-regulated genes and in red the down-regulated genes. (D) NRF2
pathway as obtained from Wiki Pathways was drawn with Cytoscape. Genes boxes were coloured according to the log2FC values, from blue (low) to red (high). (E–F)
Left: graph represents ROS levels measured by relative increase in CM-H2DCFDA fluorescence (percentage of the fluorescence value in control neurons) over time
after administration of DMNQ to differentiating SVZ-neurons (E) and M-neurons (F) at 7 DIV. Right: Slope values of the curves shown left (the lower the slope, the
larger the ROS scavenging capacity). α5 treated SVZ-neurons (green line) and M-neurons (red line) show a reduced increase in CM-H2DCFDA fluorescence intensity
implying accelerated ROS detoxification. For each condition CRL and α5 n = 6 independent experiments, linear regression analysis was used to determine the slopes.
Statistical differences between slopes were calculated by using the Analysis of Covariance (ANCOVA) test. Data are presented as mean ± SEM. *=p < 0.05; **=p<
0.01; ***=p< 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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phosphorylation [7–9,12,75]. Proliferating NSCs of the brain ventricle
are highly glycolytic and switch towards oxidative metabolism while
migrating to the upper cortical layers to become cortical neurons. In-
hibition of glycolysis in SVZ NSCs modifies the number of differentiated
neurons migrating to the cortex [75]. Similarly, the inhibition of oxi-
dative metabolism impairs neuronal differentiation driving NSCs to a
more proliferative and less differentiated state [12]. Our results con-
firmed that, together with a change in morphology, differentiating
neural precursor shift their metabolism towards oxidative metabolism.
To better define the relationship between metabolism and neuronal
differentiation, we induced a branched-chain amino acids-driven me-
tabolic shift in differentiating neurons. We found that this treatment
increased the energy metabolism of differentiated neurons. Interest-
ingly this analysis further revealed an increase of the metabolic plas-
ticity of treated neurons, by means of increasing spare respiratory ca-
pacity and glycolytic reserve. This property may help the treated cells
to maintain appropriate energetic metabolism in conditions of meta-
bolic stress. Although, the overall energy metabolism can be measured
by ECAR and OCR, the precise relative contribution of basal glycolysis
is rather difficult to assess as far as other metabolic sources may con-
tribute to the acidification of the extracellular medium, including the
CO2 released from TCA cycle [43] and the decarboxylation reactions
catalysed by glucose-6 phosphate dehydrogenase and/or pyruvate de-
hydrogenase [76].
Together with the increase in energy metabolism, we found in-
creased dendritic branching, presence of mature spine types and the
amount of presynaptic vesicles, usually considered markers of SVZ- and
M- neuron maturation [54].
To satisfy all the anabolic needs, differentiating neurons increase
their cellular energy requirement along with protein and membrane
synthesis. AMP-activated protein kinase (AMPK) is the main sensor of
low cellular energy status as it is activated by high concentration of
AMP and inhibited by high levels of ATP [74]. On the other hand,
mTOR is a central integrator of nutrient and growth factor signals that
activates many biosynthetic pathways, especially protein translation
[56]. In the regulation of cellular metabolism, AMPK function anti-
thetically to mTORC1. AMPK inhibits mTORC1 activity [77]. ATP is a
potent allosteric inhibitor of the AMPK and high cellular ATP con-
centration decreases AMPK activity and increases mTOR signalling
[74]. Similarly, amino acids, including leucine, directly activate
mTORC1 complex trough a fine tuned multiprotein nutrient sensing
complexes [13]. During neuronal differentiation, concomitant to the
increase of the oxidative metabolism, mTORC1 complex activation
promotes neural cell differentiation [11,57,58,78]. Sustained activation
of mTORC1 leads to a decrease of proliferative NSC in the SVZ [59]. In
addition, newly-born neurons in the olfactory bulb shows substantially
higher levels of pS6 K1 than neighbouring neurons [78]. Similarly,
mTORC1 activation increases dendritic complexity, synaptic formation
and plasticity [58,79–83]. In line with current knowledge, we observed
that α5 treatment highly enhanced (2–3 fold increase) both oxidative
metabolism and ATP production. As expected, we confirmed that this
was associated with increased mTORC1 expression and pS6 K1 phos-
phorylation. In condition of high energy, nutrient and growth factors,
mTORC1 activation stimulates biosynthetic pathways. Accordingly, we
found an increase in protein synthesis and mitochondrial protein
translation. Our results indicated that mTORC1 activation is required
for neuronal differentiation, since its inhibition abolished the branched-
chain amino acids-driven increase in neuronal branching. Other me-
chanisms, including mitochondrial fusion and oxidative phosphoryla-
tion may play a role in the observed effect on neuronal differentiation.
Both mitochondrial fusion and oxidative phosphorylation contribute to
increase energy availability that enhances mTORC1/S6K1 activation.
To our knowledge, these data show for the first time that supple-
mentation of specific nutrients can up-regulate the energy metabolism
and the mTOR anabolic pathway in differentiating neurons.
Not surprisingly, the increase in dendrite branching, distribution of
the synaptic marker Synaptophysin and spine maturation, were asso-
ciated with proper mitochondrial network modifications [9]. Our data
suggested that the increase of mitochondrial distribution and the me-
tabolic shift to energy metabolism were not the consequence of in-
creased mitochondrial mass or oxidative phosphorylation enzymes.
However, differentiating neurons have a particular dependence on
precise control of mitochondrial fission and fusion dynamics [62–64].
In differentiating neurons, elongated mitochondrial networks are more
efficient as energy producers and are capable of distributing energy also
through dendrites [62,69,84]. We found that treated SVZ- and M-neu-
rons increased oxidative phosphorylation, mitochondrial respiration
and ATP production, and modulated the amount of proteins involved in
mitochondrial dynamics with the remodelling of mitochondrial net-
work. Accordingly, α5 treatment increased neuronal mitochondrial
area, mitochondrial length and synergistic up-regulate the pro-fusion
and down-regulate the pro-fission proteins, thus shifting the balance of
mitochondrial dynamics toward pro-fusion event. The observed in-
crease of OPA1 (both long and short isoforms) could tight the structure
of the mitochondrial cristae favouring supercomplexes assembly [85],
and therefore increasing mitochondrial respiration [65,86,87], as we
detected by OCR. Furthermore, OPA1 elongates the mitochondrial
network (together with DRP1 decrease) by promoting mitochondrial
Fig. 6. α5 treatment drives presistent oxidative metabolic shift and increasesmitochondrial distribution and neural differentiation in human iPSCs.
(A) Immunostaining showing positivity for the expression of pluripotency markers Alkaline Phosphatase (AP, red), Tra-1-60 (green) and Stage-specific embryonic
antigen-4 (SSEA-4, red) in human iPSCs-derived neurons. Nuclei are stained with DAPI (blue). Scale bar, 20 μm. (B) In vitro iPSC differentiation displaying im-
munoreactivity for mesodermal (desmin, green) endodermal (AFP, red) and ectodermal (ßIII-tubulin, green) germ layer markers. Nuclei are stained with DAPI (blue).
Scale bar: 10 μm. (C) RT-PCR showing the expression of pluripotency-associated genes Sex determining region Y-box 2 (Sox2), Octamer-binding transcription factor
3/4 (Oct3/4) and Homeobox protein Nanog (Nanog). (D) In vitro iPSC differentiation into motor neurons expressing the motor neuron marker HB9 (red). (E)
Seahorse analysis of OCR parameter showing that human iPSCs-derived neurons supplemented with α5 (red) displayed a higher respiration rate compared to controls
(light blue). (E–F) Graphs showing that α5 supplemented human iPSCs-derived neurons displayed a higher basal (F) and maximal respiration (G), accompanied by an
increased ATP production (H) (n = 6 independent experiments). (I) Energy map of human iPSCs-derived neurons, representing basal metabolic rate metabolic
response after the inhibition of the ATP synthase with oligomycin and the administration of mitochondrial uncoupler FCCP. α5-treated human iPSCs-derived neurons
have higher energetic metabolism compared to untreated cells at the basal state, display higher spare respiratory capacity (J), and similar glycolytic compensation
(glycolytic reserve) in response to the blunt of mitochondrial ATP production (K). Data are extrapolated from the Mitostress test; see suppl. (L) Immunostaining of
human iPSCs-derived neurons for the mitochondrial marker Tomm20. Nuclei are stained with DAPI (blue). Scale bar: 20 μm. (M) Immunostaining of human iPSCs-
derived neurons for ßIII-tubulin (Tub3, green). Nuclei are stained with DAPI (blue). Scale bar: 10 μm. (N) Immunostaining of human iPSCs-derived neurons for the
mitochondrial marker Tomm20 (grey in the left panel and red in the right panel) and ßIII-tubulin (Tub3, green). Scale bar: 10 μm. (O) Graph representing the
percentage of Tomm20 expression area normalized for ßIII-tubulin expression area. The percentage of Tomm20 coverage was increased compared to CRL. (P) Graph
representing mitochondria percentage classification on the basis of their length among the total quantified mitochondria showing that the percentage of elongated
mitochondria statistically increases following α5 treatment, while the intermediated one decreases. (Q) Graph represents the fold-increase of α5 treated samples
compared to control (CRL) of ßIII-tubulin expression area normalized for the total nuclei number. The expression area of Tub3 was increased compared to CRL
suggesting higher neuronal differentiation and dendrite extension. Data are presented as mean ± SEM. *=p < 0.05; **=p< 0.01; ***=p< 0.001, ****=p<
0.0001. For immunostaining quantification at n = 6 independent experiments and at least 6 technical replicates for each n were considered. Scale bars are 50 μm (A,
B, D). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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fusion [72], as we showed by western blot and immunofluorescence
analysis. These observations suggest that α5 effect may increase re-
spiratory complex activities through mitochondrial re-shaping.
In this work we found that activation of mTORC1/S6K1 pathway
was associated to an increase of mitochondrial fusion events. Previous
work showed that mTORC1 activation has been shown to drive mi-
tochondrial division in a 4E-BP-dependent mechanism [88]. We think
that the reason of the distinct effects of mTORC1 signalling activation
on mitochondrial fusion may mostly reside in the different cell types
studied, which are highly proliferating mouse embryonic fibroblast
[88] and murine and human post-mitotic differentiated neurons (our
work). The increase in ATP energy content is a necessary requirement
for differentiating neurons. In this context mTORC1/S6K1 signalling
activation may be a mediator of increased energy metabolism (ATP
production) in neuronal cells, and therefore, required for dendrites
maturation. In line with this, it has been elegantly shown that oxidative
culture conditions (as the ones that we applied) stimulate oxidative
phosphorylation and mitochondrial elongation [89]. More generally,
mitochondrial elongation has been linked to increased oxidative phos-
phorylation in different cell types [90] and, recently, also through an
mTORC1-mediated mechanism [91].
Interestingly, together with the increase in oxidative metabolism
and mitochondrial fusion, we observed a significant functional im-
provement of antioxidant defences in α5 treated neurons. Neurons are
highly dependent on oxygen metabolism for their function, thus re-
quiring proper antioxidant defences. The increase in oxygen radical
detoxification and the maintenance of an appropriate redox home-
ostasis help to protect neurons against brain ischemia [33].
Furthermore, aging and neurodegenerative diseases have been shown
to be associated with a loss of neuronal mitochondria and an increase of
radical oxygen species damage. Both our transcriptomic (RNA sequen-
cing) and functional data suggested that α5 treated neurons increased
their antioxidant defence. Interestingly, the up-regulation of the anti-
oxidant NRF2 pathway, observed in α5 treated neurons, may also
contribute to enhance the mitochondrial fusion pattern as it increased
proteasomal activity and selective degradation of the mitochondrial
fission protein Drp1 [92].
Recently, the availability of specific metabolic precursors has been
shown to favour neural cell differentiation. An increase of serine and
cysteine pools can promote oligodendrocytes differentiation [93]. Si-
milarly, administration of branched-chain amino acid has been shown
to ameliorate cognitive impairments in mice models of traumatic brain
injury [20,23]. Our data showed that cellular metabolism can be
modulated to increase neuronal differentiation. Following the addition
of brain-chain aminoacid, TCA cycle intermediates and co-factors,
neural differentiating cells increased: i) energy metabolism; ii) neuronal
maturation and iii) neuronal antioxidant defence. We speculate that the
possible mechanisms responsible of this process may involve the sy-
nergistic action of ATP production and the activation of both mTORC1
and NRF2 pathways (Fig. 7).
These findings suggest that a branched-chain amino acids-driven
modulation of the neuronal metabolism towards energy metabolism
may be an effective approach to induce complete neural differentiation.
This approach may be an exploitable therapy to improve neuronal
survival, regeneration, and maturation in neurodegenerative diseases,
including stroke, traumatic brain injury and spinal cord injury.
Fig. 7. Schematic representation of the po-
tential mechanisms of action of branched-
chain aminoacids on neuronal differentia-
tion.
Scheme representing the potential mechanisms
of action of α5 treatment on differentiating
neurons. α5 (yellow box) may increase the
overall energy metabolism (light orange box)
that include tricarboxylic acid cycle (TCA)
cycle flux through anaplerotic reactions
(amino acids breakdown), oxidative metabo-
lism, and mitochondrial fusion. Elongated mi-
tochondria are associated with increased oxi-
dative phosphorylation activity and ATP
production. The increase in ATP cellular con-
tent activates mTORC1/S6 K1 and reduces
AMPK activity, a major inhibitor of mTORC1.
Amino acids contained in α5, especially bran-
ched-chain amino acids (valine, leucine and
isoleucine) are known nutrient sensors that
directly activate mTORC1/S6 K1 anabolic ac-
tivity. The increase in oxidative metabolism
and oxygen consumption may increase the
Reactive Oxygen Specie (ROS) content that in
turn can activate the antioxidant NRF2
pathway. Moreover, we observed that α5
treatment increased the metabolic plasticity,
which is oxidative and glycolytic reserve of the
differentiating neurons. The improved
mTORC1/S6 K1 anabolic activity increases
protein synthesis and it is instrumental for the
increase of neuronal differentiation. This, to-
gether with the increase in metabolic plasticity
and antioxidant defence, may contribute to
enhance neuronal differentiation. (For inter-
pretation of the references to colour in this
figure legend, the reader is referred to the web
version of this article).
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